Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q1 EPS of $1.20, $0.26 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $88.18 million versus the consensus estimate of $99.12 million.

FY 2025 Guidance:
Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expense(1) $150.0 - $175.0

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.